Using The Cancer Genome Atlas (TCGA) data on lung adenocarcinoma and endocrine receptor (ER)-positive breast cancer, 28 to 38% of the combinations predicted using DrugComboRanker showed evidence of positive effects consistent with the published literature9. The gene discussed is ESR1; the disease is breast cancer.